Please login to the form below
vaccines
This page shows the latest vaccines news and features for those working in and with pharma, biotech and healthcare.
BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
From a strategic standpoint, the new site will bolster our vertically integrated business model with in-house manufacturing capabilities for mRNA manufacturing as well as vaccine formulation,” he added. ... The initiative is focused on expanding the
Latest news
-
Sanofi, GSK to launch human trials of COVID-19 vaccine
In July, the UK government agreed a deal with the drugmakers for 60 million doses of the protein-based vaccine. ... A week later, Sanofi and GSK forged another agreement with the US government for 100 million doses of their vaccine.
-
Valneva announces major COVID-19 vaccine partnership with UK government
Two-dose vaccine candidate scheduled to enter first clinical studies in December 2020. ... Valneva is using a proven approach as the base for its vaccine candidate, VLA2001.
-
Trials resume for AZ/Oxford University COVID-19 vaccine
Investigations were conducted to identify if the adverse reaction was linked to the vaccine. ... We will back our scientists to deliver an effective vaccine as soon as safely possible.".
-
AZ pauses COVID-19 vaccine study after participant falls ill
The results, published in The Lancet in July, showed that the vaccine produced a robust immune response against the virus in all participants in the study. ... In this early study, the vaccine appeared safe to use, although side effects were common among
-
Top biopharma CEOs sign COVID-19 vaccine safety pledge
and Sanofi and GlaxoSmithKline, the companies that are leading joint vaccine projects respectively, and stated:. ... Work to ensure a sufficient supply and range of vaccine options, including those suitable for global access.'.
More from news
Approximately 126 fully matching, plus 1,132 partially matching documents found.
Latest Intelligence
-
Exploiting the value of data in pharma
the world’s leading pharma companies ‘to accelerate the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19’. ... Accelerate development. Again, in March, the Innovative Medicines Initiative (IMI) issued a
-
What’s next? How behavioural science can support pharma’s future
behaviour. Vaccines to protect against a range of diseases are likely to be more widely and more quickly adopted, by all customer types.
-
A new era for patient services?
Importantly, the role industry is playing in leading efforts to find and manufacture effective COVID-19 treatments and a vaccine will likely have a positive impact on public and healthcare system
-
Why pharma must trust the science of behaviour
In the absence of a treatment or vaccine, behaviour change remains our best hope of thwarting COVID-19. ... However, while we await a vaccine, those behaviours are currently the best weapon we have.
-
The search for treatments for Parkinson’s disease
Two years on, there is real conviction that transformative therapies, in the shape of disease-modifying drugs, gene therapy, growth factors, vaccines and repurposed drugs along with potential biomarkers offer a
More from intelligence
Approximately 6 fully matching, plus 104 partially matching documents found.
Latest appointments
-
Evoke KYNE promotes Dante DelVecchio to senior VP
In his new role, he will become a member of the firm’s senior management team, and will continue to oversee key client engagements in infectious diseases, vaccines and immuno-oncology.
-
New hires at Bayer, Eisai and Accord Healthcare
Most recently, she held the position of vice president of M&A operations and divestitures and led the infectious diseases and vaccines business development. ... She joins Eisai from Merck, where she served as executive director, clinical quality assurance
-
Bone Therapeutics strengthens board with new chairman
He has also been a member of the corporate executive team for GlaxoSmithKline and chief executive officer of GSK Biologicals (now GSK Vaccines).
-
McCann Health appoints Daniel Carucci as global medical director
Dr Carucci has over 25 years of experience in large-scale innovation programs, vaccine development, organisational leadership, and global public health, during which time he served as VP for global health
-
Professor Carole Longson moves from NICE to the ABPI
and the role our members play in developing new innovative medicines and vaccines.
More from appointments
Approximately 5 fully matching, plus 63 partially matching documents found.
Latest from PMHub
-
August 2020: diversity and inclusion in clinical trials round-up
Dr Borno said, “I think that if we do not ensure diversity in these COVID-19 clinical research studies, we may ultimately render interventions, whether it be drug or vaccines, that
-
Case study
vaccine. Read the full case study here: . 44 (0) 20 8069 5000. Address:. Chester House. Fulham Green. 81-83 Fulham High Street.
-
White paper helps industry navigate new NHS roadmap
development of Covid-19 drugs and vaccines.
-
July 2020: diversity and inclusion in clinical trials round-up
Marina Martin, an assistant professor and section chief of Geriatric Medicine at Stanford Medicine, said “With vaccine research, if we only test a vaccine in a younger population, we run the ... Recommendations to ensure all women are included in
-
Secondary effects of COVID-19 on the healthcare system and patients
To date, most of the focus has understandably been on the immediate effects of the virus and the efforts to enforce physical distancing and develop a vaccine.
More from PMHub
Approximately 6 fully matching, plus 40 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Roche’s Ocrevus boasts positive long-term data in MS
- Leadership change within Bedrock Group
- Lilly starts large-scale trial of tirzepatide in diabetic heart disease
- Live Webinar: Telemedicine & the Digitization of Medicine post COVID-19
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
